De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.

医学 帕妥珠单抗 曲妥珠单抗 乳腺癌 内科学 临床终点 肿瘤科 新辅助治疗 代理终结点 癌症 临床试验
作者
Ulrike Nitz,Oleg Gluz,Monika Graeser,Matthias Christgen,Sherko Kuemmel,Eva-Maria Grischke,Michael Braun,Doris Augustin,Jochem Potenberg,Katja Krauss,Claudia Schumacher,Helmut Forstbauer,Toralf Reimer,Andrea Stefek,Hans Holger Fischer,Enrico Pelz,Christine Zu Eulenburg,Ronald Kates,Rachel Wuerstlein,Hans Heinrich Kreipe,Nadia Harbeck
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:23 (5): 625-635
标识
DOI:10.1016/s1470-2045(22)00159-0
摘要

Several de-escalation neoadjuvant strategies have been investigated to reduce the use of chemotherapy in HER2-positive early breast cancer using pathological complete response as a surrogate endpoint; there are few survival data from these trials. Here, we report 5-year survival data in the WSG-ADAPT-HER2+/HR- trial and address the effect of pathological complete response, early therapy response, and molecular subtype.WSG-ASAPT-HER2+/HR-, a part of the ADAPT umbrella trial performed in patients with different subtypes of early breast cancer, was an investigator-initiated, multicentre, open-label, randomised, phase 2 trial done at 40 Breast Cancer Centres in Germany. Eligible patients were aged 18 years or older with histologically confirmed, unilateral, primary invasive, non-inflammatory early breast cancer, hormone receptor-negative and HER2-positive status, and an Eastern Cooperative Oncology Group performance status of 0 or 1 or a Karnofsky performance status of at least 80%. Patients were randomly assigned (5:2, block size 21, stratified by centre and clinical nodal status) to 12 weeks of either trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks) plus pertuzumab (840 mg loading dose, then 420 mg every 3 weeks) or trastuzumab plus pertuzumab plus paclitaxel (80 mg/m2 weekly); all drugs were administered intravenously. The primary objective of the trial was to compare the number of patients with a pathological complete response at surgery (ie, no invasive tumour cells in breast and lymph nodes [ypT0/is ypN0], the primary endpoint) in early responders (ie, low cellularity or Ki67 decrease ≥30% after 3 weeks) in the trastuzumab plus pertuzumab group versus all patients (irrespective of an early response) in the trastuzumab plus pertuzumab plus paclitaxel group. Non-inferiority was defined as a pathological complete response no worse than 23% lower in the early-responder proportion of patients in the trastuzumab plus pertuzumab group than in the entire trastuzumab plus pertuzumab plus paclitaxel group. The primary endpoint has been reported previously. Additionally, the primary objective of the ADAPT umbrella trial was the evaluation of the effect of pathological complete response on invasive disease-free survival. At investigator's discretion, further chemotherapy could be omitted in patients with a pathological complete response. Secondary survival endpoints were 5-year invasive disease-free survival, relapse-free survival, locoregional relapse-free survival, distant disease-free survival, and overall survival. The effect of pathological complete response on survival was estimated by Cox regression analysis. All analyses are reported in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01817452, and is closed to recruitment.Between March 3, 2014, and Oct 6, 2015, 134 patients were recruited and randomly assigned to treatment, 92 to trastuzumab plus pertuzumab and 42 to trastuzumab plus pertuzumab plus paclitaxel. Median follow-up in survivors was 59·9 months (IQR 53·4-61·4). There were no significant differences between the treatment groups in invasive disease-free survival, relapse-free survival, locoregional relapse-free survival, distant disease-free survival, and overall survival. In the trastuzumab plus pertuzumab plus paclitaxel group and in the trastuzumab plus pertuzumab group, the proportions of patients achieving 5-year survival respectively were 98% (95% CI 84-100) and 87% (78-93) for invasive disease-free survival (hazard ratio [HR] 0·32, 95% CI 0·07-1·49; p=0·15); 98% (95% CI 84-100) and 89% (79-94) for relapse-free survival (HR 0·41, 95% CI 0·09-1·91; p=0·25); 100% (95% CI not estimable) and 95% (88-98) for locoregional relapse-free survival (HR 0·41, 95% CI 0·05-3·75; p=0·43); 98% (95% CI 84-100) and 92% (83-96) for distant disease-free survival (HR 0·35, 95% CI 0·04-3·12; p=0·36), and 98% (95% CI 84-100) and 94% (86-97) for overall survival (HR 0·41, 95% CI 0·05-3·63; p=0·43). Pathological complete response was associated with improved invasive disease-free survival (HR 0·14, 95% CI 0·03-0·64; p=0·011). Two invasive disease-free survival events occurred after a pathological complete response (one in each treatment group).The WSG-ADAPT-HER2+/HR- trial showed good survival rates in patients with a pathological complete response after de-escalated 12-week trastuzumab plus pertuzumab with or without weekly paclitaxel. Omission of further chemotherapy did not affect invasive disease-free survival in patients with a pathological complete response. 12 weeks of weekly paclitaxel plus dual HER2 blockade could be an efficacious de-escalated neoadjuvant regimen in patients with hormone receptor-negative, HER2-positive early breast cancer with high pathological complete response rates and good 5-year outcomes. Further trials of this approach are ongoing.Roche, Bayer.For the German translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
等待的剑身完成签到,获得积分10
刚刚
liiiiiii发布了新的文献求助10
刚刚
Kate发布了新的文献求助10
刚刚
1秒前
小玉发布了新的文献求助10
1秒前
2秒前
4秒前
zq发布了新的文献求助10
4秒前
4秒前
浮生若梦完成签到 ,获得积分10
5秒前
无心的尔阳完成签到 ,获得积分10
5秒前
5秒前
5秒前
7秒前
内向忆南发布了新的文献求助10
7秒前
meihui完成签到 ,获得积分10
7秒前
CipherSage应助enttt采纳,获得10
8秒前
8秒前
艾琳克斯完成签到 ,获得积分10
8秒前
dpp发布了新的文献求助10
9秒前
9秒前
liiiiiii完成签到,获得积分20
9秒前
魔幻秋烟完成签到 ,获得积分10
10秒前
彩虹天堂完成签到,获得积分10
10秒前
yi蔚完成签到,获得积分10
11秒前
林瓜瓜发布了新的文献求助10
11秒前
cxwcn发布了新的文献求助10
11秒前
meihui发布了新的文献求助10
12秒前
Jin发布了新的文献求助10
13秒前
13秒前
张北海举报嘚嘚求助涉嫌违规
14秒前
稻草人发布了新的文献求助10
14秒前
赘婿应助玉玉采纳,获得10
15秒前
净净子完成签到 ,获得积分10
16秒前
愉快的Jerry完成签到,获得积分10
17秒前
Jin完成签到,获得积分20
17秒前
Zenia完成签到,获得积分10
18秒前
18秒前
可爱的函函应助suiwuya采纳,获得10
19秒前
852应助kk采纳,获得10
19秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Indomethacinのヒトにおける経皮吸収 400
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 370
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
Current Perspectives on Generative SLA - Processing, Influence, and Interfaces 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3992317
求助须知:如何正确求助?哪些是违规求助? 3533285
关于积分的说明 11261852
捐赠科研通 3272704
什么是DOI,文献DOI怎么找? 1805867
邀请新用户注册赠送积分活动 882732
科研通“疑难数据库(出版商)”最低求助积分说明 809459